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A Step Forward in the Treatment of Influenza
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Disease Control and Prevention, Atlanta
For many years, antiviral treatment of influenza has consisted of monotherapy with a 
neuraminidase inhibitor. The Food and Drug Administration (FDA) approved the 
neuraminidase inhibitors oseltamivir (oral administration) and zanamivir (oral inhalation) in 
1999 and peramivir (intravenous administration) in late 2014. These drugs work by binding 
to the viral neuraminidase protein and interfering with the release of influenza virus particles 
from infected respiratory tract cells. Neuraminidase inhibitors are FDA-approved for the 
treatment of uncomplicated influenza within 2 days after onset in outpatients, on the basis of 
randomized, controlled trials, but they are also recommended for the treatment of patients 
with severe influenza, including hospitalized patients, by the Centers for Disease Control 
and Prevention and the World Health Organization.1,2 The adamantane antiviral drugs 
(amantadine and rimantadine) are approved for the treatment of influenza A virus infections 
but are not recommended, owing to a high prevalence of adamantane resistance among 
circulating influenza A viruses.1
Because influenza viruses are continuously evolving, global surveillance of circulating 
influenza viruses is essential to inform recommendations on the use of antiviral drugs for 
influenza. This was highlighted by the emergence of oseltamivir-resistant influenza 
A(H1N1) viruses in 2007 that became prevalent worldwide until replacement by the 2009 
H1N1 pandemic virus (influenza A(H1N1)pdm09).3 Sporadic emergence of oseltamivir 
resistance, including clusters of oseltamivir-resistant influenza A(H1N1)pdm09 virus 
infections, further emphasizes the need for drugs with mechanisms of action distinct from 
neuraminidase inhibitors.3
In this issue of the Journal, investigators report the results of two randomized, double-blind, 
placebo-controlled trials of baloxavir marboxil (baloxavir), a new antiviral drug that targets 
the polymerase complex of influenza A and B viruses.4 After oral administration, baloxavir 
is converted to baloxavir acid, which selectively inhibits the function of endonuclease within 
the polymerase acidic (PA) protein subunit of influenza viral polymerase. The trials involved 
outpatients 12 to 64 years of age without underlying high-risk medical conditions who 
presented within 48 hours after the onset of laboratory-confirmed influenza in Japan and the 
United States. In the phase 2 dose-ranging trial involving 389 Japanese adults, a single 
baloxavir dose (10 mg, 20 mg, or 40 mg) resulted in a significantly shorter time to 
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alleviation of symptoms and greater reductions in levels of influenza virus at 1 and 2 days 
after administration of the trial regimen than did placebo. In the phase 3 trial in Japan and 
the United States, patients 20 to 64 years of age were randomly assigned to receive a single 
dose of baloxavir (40 mg or 80 mg, depending on body weight), oseltamivir at a dose of 75 
mg twice daily for 5 days, or placebo; patients 12 to 19 years of age were assigned to receive 
either baloxavir or placebo. Among the 1064 patients who had a diagnosis of influenza 
confirmed by a reverse transcriptase–polymerase chain reaction assay, baloxavir resulted in a 
significantly shorter time to alleviation of symptoms than did placebo in patients 20 to 64 
years of age (median difference, 25.6 hours) and those 12 to 19 years of age (median 
difference, 38.6 hours). However, there was no significant difference in the median time to 
alleviation of symptoms between baloxavir recipients and oseltamivir recipients.
These findings indicate that baloxavir has a clinical benefit that is similar to that with 
oseltamivir for the early treatment of otherwise healthy outpatients 12 to 64 years of age 
with uncomplicated influenza. Owing to its longer half-life, a single baloxavir dose provides 
the advantage of avoiding adherence concerns with treatment with 5 days of twice-daily 
oseltamivir. However, in the phase 3 trial, more than half the patients in the baloxavir group 
received the drug within 24 hours after symptom onset, and such patients had a greater 
clinical benefit regarding a reduction in the duration of influenza symptoms than those who 
received it later. This is consistent with data on neuraminidase inhibitors — the greatest 
clinical benefit is when antiviral treatment is started soon after the onset of influenza. Thus, 
implementing early treatment with baloxavir or neuraminidase inhibitors will remain 
challenging for clinicians and patients with influenza worldwide.
The virologic findings of single-dose baloxavir treatment are both encouraging and cause for 
concern. In the phase 3 trial, baloxavir resulted in significantly greater reductions in 
influenza viral RNA levels in upper respiratory specimens at 24 hours and a shorter duration 
of infectious virus detection than did oseltamivir or placebo. However, in both trials, 
baloxavir treatment induced the emergence of viral escape mutants with reduced 
susceptibility through changes from isoleucine to other amino acids at position 38 (I38) of 
the gene encoding PA. Influenza A(H1N1) pdm09 virus was the predominant virus among 
patients in the phase 2 trial, and 2.2% of the baloxavir recipients with paired sequenced 
samples had escape mutants. In the phase 3 trial, influenza A(H3N2) virus predominated, 
and 10% of the baloxavir recipients with paired sequenced samples had escape mutants 
detected, typically 5 days or more after baloxavir treatment. Furthermore, in the phase 3 
trial, infectious virus was detected 5 days after baloxavir treatment in 91% of the patients 
with escape mutations conferring a switch at I38 to threonine or methionine (I38T/M), and 
their duration of symptoms was substantially longer than the duration in baloxavir recipients 
without these escape mutants. In a related, but separate, cohort study involving children, 
19.5% of baloxavir recipients had I38T mutations detected, and these escape mutants 
conferred reduced susceptibility to baloxavir by a factor of 30 to 50 in influenza A viruses 
and by a factor of 7 in influenza B viruses.5 The issue for public health is whether these 
influenza viruses with reduced susceptibility to baloxavir are transmissible, and surveillance 
for I38T and other markers will be needed.6 A related study showed that viruses with these 
escape mutants had impaired replicative fitness in in vitro experiments, which suggests 
lower transmissibility.5
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These two randomized, controlled trials reported in the Journal should be viewed as a first 
step and the findings tempered by the need for data on baloxavir efficacy and safety through 
clinical trials involving patients with influenza who are most likely to benefit from antiviral 
treatment. These include persons at higher risk for influenza complications because of age 
(young children and elderly persons), pregnancy, or chronic coexisting medical conditions. 
Data are also needed on the clinical benefit of administering baloxavir treatment more than 
48 hours after illness onset to outpatients who are in a high-risk group and to patients of all 
ages who are hospitalized with severe influenza complications, including critical illness. 
Pharmacokinetic and pharmacodynamic data are needed to inform appropriate dosing and to 
determine whether additional baloxavir doses are beneficial in patients with severe 
influenza. Can combination treatment with oseltamivir and baloxavir provide greater clinical 
benefit than oseltamivir monotherapy in hospitalized patients and severely 
immunocompromised patients with seasonal influenza, as well as in hospitalized patients 
with zoonotic influenza, such as those with avian influenza A(H7N9) virus infection? Can 
baloxavir successfully treat patients with neuraminidase inhibitor–resistant influenza virus 
infection?
The significant reduction in influenza viral replication with baloxavir treatment suggests the 
potential for reducing influenza virus spread to close contacts and should be studied through 
randomized, controlled trials in households and during institutional influenza outbreaks such 
as in long-term care facilities. If a single dose is successful in reducing influenza virus 
transmission, baloxavir could be a useful tool for seasonal and pandemic influenza 
preparedness and response. Further clinical, virologic, and transmission studies, and global 
surveillance for influenza viruses with reduced drug susceptibility, will inform the 
usefulness of baloxavir for clinical use and public health benefit.
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